New Insights and Future Perspectives of APRIL in IgA Nephropathy
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910340 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Masahiro Muto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Tumor Necrosis Factor Ligand Superfamily Member 13. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
IgA nephropathy (IgAN) is characterized by immune-mediated glomerulonephritis, with the accumulation of galactose-deficient IgA1 (Gd-IgA1) in the glomeruli and increased levels of circulating Gd-IgA1 and Gd-IgA1-containing immune complexes. An incomplete understanding of the underlying mechanisms and differences in clinical and pathological features between individuals and ethnicities has contributed to the lack of established treatments for IgAN. A tumor necrosis factor (TNF) family member, a proliferation-inducing ligand (APRIL), is a crucial cytokine essential for the generation and survival of plasma cells. Recent studies demonstrated that APRIL is a pivotal mediator in the production of Gd-IgA1 in IgAN. As our understanding of the autoimmune pathogenesis underlying IgAN has improved, various pharmacological therapeutic targets, including APRIL antagonists, have emerged. Preliminary results showed that APRIL-targeting agents effectively reduced proteinuria and Gd-IgA1 levels without significantly increasing adverse events, indicating their potential as novel therapeutic agents for IgAN. In the present review, we discuss the current understanding of the role of APRIL in the pathogenesis of IgAN and novel therapeutic strategies focusing on APRIL-targeting agents for IgAN. APRIL inhibitors may offer new hope to patients with IgAN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan.
- Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.
ORCID-Profile: Hitoshi Suzuki
Förderung
- JSPS KAKENHI
Zitieren
APA
Muto, M., Suzuki, H., & Suzuki, Y. (2024). New Insights and Future Perspectives of APRIL in IgA Nephropathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910340
Vancouver
Muto M, Suzuki H, Suzuki Y. New Insights and Future Perspectives of APRIL in IgA Nephropathy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910340
BibTeX
@article{Muto2024,
author = {Muto, Masahiro and Suzuki, Hitoshi and Suzuki, Yusuke},
title = {New Insights and Future Perspectives of APRIL in IgA Nephropathy},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910340}
}
EUVIMED